Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCP-001 |
Synonyms | |
Therapy Description |
DCP-001 is a leukemia cell line-derived allogeneic dendritic cell vaccine that expresses several tumor-associated antigens and potentially induces an anti-tumor immune response (PMID: 30039426, PMID: 34831455). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCP-001 | Allogeneic AML antigen-expressing dendritic cell vaccine|DCOne | DCP-001 is a leukemia cell line-derived allogeneic dendritic cell vaccine that expresses several tumor-associated antigens and potentially induces an anti-tumor immune response (PMID: 30039426, PMID: 34831455). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04739527 | Phase I | DCP-001 | Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment (ALISON) | Active, not recruiting | NLD | 0 |